A recent study reveals that immunosuppression, or reduced immune response, in prostate cancer is associated with a ...

The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic ...

Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It ...

AstraZeneca AZN has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen ...

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

High-level results from the company’s ongoing CAPltello-281 phase 3 study demonstrated that a combination of Truqap, Johnson ...

The following is a summary of “High 11-ketotestosterone linked to shorter time to castration resistance in recurrent ...

AstraZeneca (AZN) reported positive results from a Phase 3 study of its drug Truqap in the treatment of a certain type of ...

AstraZeneca (AZ) has announced positive high-level results from a late-stage study of its AKT inhibitor Truqap (capivasertib) ...

Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.

Diet is increasingly seen as a modifiable risk factor in prostate cancer. Recent studies have shown that ...